Fan Zhang, DO
Neurology · Las Vegas, NVNPI 1659735017
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $284,476 of the $397,563 with a category attached, or 71.6%. Neurocrine Biosciences, Inc. accounts for 75.1% of it on its own, with 57 other manufacturers making up the rest. 2025 is the largest year on record at $139,921, more than ten times the $646 reported in 2019. Among neurology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,517 payments — averaging $262.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$299K
- Abbott$60K
- Medtronic$13K
- Merz Pharmaceuticals, LLC$11K
- AbbVie$3K
- Boston Scientific$2K
- plus $9K from 52 others
What the payments were for
- Consulting fees$32,0548%
- Speaking & faculty fees$284,47672%
- Travel & lodging$37,6849%
- Food & beverage$43,21111%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$289,757
- INFINITY$57,719
- INBRIJA$11,140
- PERCEPT PC BRAINSENSE$8,846
- VERCISE$1,186
- ACTIVA$949
- SenSight$830
- GENERAL DBS$345
- Pipeline$311
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$263
- PROCLAIM$246
- AlinIQ$197
- Percept$173
- Infinity DBS Pulse Generators$123
- ONGENTYS 50MG CAPSULES 30$116
- Duopa$115
- NUPLAZID$110
How this compares
$397,563 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 135 | $1,152,655 |
| NuplazidPimavanserin Tartrate | 70 | $339,096 |
| AustedoDeutetrabenazine | 19 | $213,897 |
| RytaryCarbidopa/Levodopa | 37 | $73,530 |
| BotoxOnabotulinumtoxina | 58 | $72,181 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,120 | $24,198 |
| NourianzIstradefylline | 12 | $22,674 |
| InbrijaLevodopa | 11 | $20,468 |
| OngentysOpicapone | 21 | $15,018 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 517 | $14,853 |
| Primidone | 574 | $14,194 |
| AmantadineAmantadine Hcl | 167 | $8,555 |
| Ropinirole ErRopinirole Hcl | 12 | $3,401 |
| Gabapentin | 192 | $3,083 |
| Selegiline Hcl | 15 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $298,572 | $1,167,672156 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,048 | $339,09670 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $637 | $213,89719 claims |
| Amneal Pharmaceuticals LLCRytary | $436 | $73,53037 claims |
| AbbVieBotox | $3,357 | $72,18158 claims |
| Kyowa Kirin, Inc.Nourianz | $207 | $22,67412 claims |
| Acorda Therapeutics, IncInbrija | $822 | $20,46811 claims |
| Upsher-smith Laboratories LLCTopiramate | $34 | $54963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
- Charles BernickLas Vegas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.